Peroxiredoxin 1 inhibits tumorigenesis by activating the NLRP3/GSDMD pathway to induce pyroptosis of colorectal cancer cells

Figure 3 Recombinant peroxiredoxin 1 inhibits motility of RKO and SW480 cells. A and B: Motility of RKO cells measured by the wound healing assay under different doses of recombinant peroxiredoxin 1 (rPrdx1) stimulation for 6, 12 and 24 hours, respectively; C and D: Motility of SW480 cells measured by the wound healing assay under different doses of rPrdx1 stimulation for 6, 12 and 24 hours, respectively. These experiments were repeated three times in independent experiments. Data are expressed as the mean ± SD. ^aP < 0.05 vs the control group (without rPrdx1); ^bP < 0.01 vs the control group (without rPrdx1).